Lobbying registration dated 2026-03-11
Registrant: Jay Strauss
Client: Best Medicines Coalition
Targeted institutions:
Intergovernmental Affairs Secretariat (IGA)
Employment and Social Development Canada (ESDC)
Public Safety Canada (PS)
Finance Canada (FIN)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Prime Minister's Office (PMO)
House of Commons
Office of the Auditor General of Canada (OAG)
Innovation, Science and Economic Development Canada (ISED)
Office of the Public Sector Integrity Commissioner (PSIC)
Global Affairs Canada (GAC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Government funding received:
Lobbying activity details:
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend the creation of a Patient Ombudsman.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Recommend the creation of a Chief Patient Officer.
Provide input on pharmacare.
Support input into the consultation on draft guidance on decentralized clinical trials.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
Support input regarding Canada’s pharmaceutical sovereignty.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Provide input on a national strategy for drugs for rare diseases.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board,  along with feedback on their policies and practices, and processes related to PMPRB.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.